For citations:
Avxentyev N.A., Frolov M.Yu., Makarov A.S. Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2018;11(2):27-37. (In Russ.) https://doi.org/10.17749/2070-4909.2018.11.2.027-037

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.